QHSLab Inc · OTC:USAQ
QHSLab — Investor Presentation (December 2025)
29 slides from QHSLab's investor presentation, Dec 1, 2025
Slide 1: Empowering Healthcare Through Digital Medicine
CG QHSLAB Empowering Healthcare Through Digital Medicine Innovation Revolutionizing Primary Care: New Vision. New Opportunities. QHSLab.com Stock Symbol: USAQ Corporate Presentation - December 2025
Slide 2: Forward-Looking Statements & Disclaimers
QHSLAB Forward-Looking Statements & Disclaimers This presentation contains “forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21€ of the Securities Exchange Act of 1934, as amended. Statements in this presentation
Slide 3: Key Takeaways for Investment
CG QHSLAB Key Takeaways for Investment Revenue Producing: QHSLab's business model generates recurring revenue for the company itself and its medical practitioner clients. This revenue comes from a large and continuously expanding addressable end market. Positioned for Growth: We are favorably aligne
Slide 4: Most Recent Quarter
@ GH Most Recent Quarter 800000 600000 400000 200000 @ 92 2024 @ 932025 2000000 1500000 1000000 500000 -500000 Robust Q3 2025 Year-Over-Year Revenue Growth, Expanded »—¥ Gross Profit, and Strengthened Operating Metrics é Annual Performance @ 102024 @ YTD 2025 Corporate Presentation - December 2025
Slide 5: Financial Highlights - Third Quarter Ended September 30, 2025
@ QGHS Financial Highlights - Third Quarter Ended September 30, 2025 Revenue: $737,066, an increase of 35% compared to $544,285 for Q3 2024. Gross profit: $493,631, up 35% from $365,133 in the prior year quarter, reflecting a gross margin of 67%. Operating income: $96,251 versus $89,090 in Q3 2024.
Slide 6: Highly-Profitable Business Model
CG QHSLAB Highly-Profitable Business Model Our scalable and straightforward business model enables providers to deliver better care while generating additional revenue. Here's how our key revenue streams break down: Allergy Diagnostic Kits: $100 per test — $12,000 annually per provider Immunotherapy
Slide 7: Leveraging Our Strengths & Competitive Advantages
CG QHSLAB Leveraging Our Strengths & Competitive Advantages Product Profile: Exclusive product line featuring FDA-cleared diagnostic equipment, widely accepted by Medicare and private insurance providers. Advanced Technology Platform: The QHSLab Expert System efficiently processes large volumes of d
Slide 8: Vision and Execution: Transforming Primary Care
QHSLAB Vision and Execution: Transforming Primary Care Our Dedicatior To revolutionize patient care through well-integrated programs not only sets new industry standards but also positively impacts the overall well-being of patients. Our Mission: To improve the quality of life for individuals and po
Slide 9: The Problem: Primary care gaps are failing millions of patients
CG QHSLAB The Problem: Primary care gaps are failing millions of patients, driving untreated conditions and worsening outcomes. Doctor Lack Time and Tool 18 minutes* per patient visit —too short for comprehensive care. 40%** of mental health issues and 50% of allergy symptoms go undiagnosed. (source
Slide 10: The True Cost of Gaps in Primary Care
Cy QHSLAB The True Cost of Gaps in Primary Care: Too Many Patients, Too Little Time leading to Overwhelmed Providers, Underserved Patients. Untreated Conditions Escalate: Millions of undiagnosed and poorly managed conditions lead to preventable complications and chronic illnesses. Quality of Care Fa
Slide 11: Intelligent Tools & Patient-Centric Health Care Technologies for Smarter Primary Care
Cy QHSLAB Intelligent Tools & Patient-Centric Health Care Technologies for Smarter Primary Care Advanced Patient Engagement: Interactive digital tools collect meaningful data from patients, uncovering hidden symptoms. Data-Driven Insights: Robust back-end organizes patient input into actionable insi
Slide 12: Transforming Patient Data into Clinical Insights and Better Health Outcomes
Cy QHSLAB Transforming Patient Data into Cl Outcomes Health Questionnaire Allergy Baseline Assessment ‘al Insights and Better Health Our Mission: Improving quality of life through physician-directed digital health and innovative point-of- care solutions. Our Goals: + Enhance patient outcomes. + Redu
Slide 13: Empowering Providers and Patients with Intelligent, Reimbursable Solutions
“@ GHSLAB Mastering Back Pin Partt atwel Diabetes Fy CG QHSLAB Empowering Providers and Patients with Intelligent, Reimbursable Solutions What It Does: A cloud-based software that engages patients, uncovers hidden conditions, and empowers physicians with actionable insights. Why It Matters: Improves
Slide 14: Integrating Mental Health & Allergic Disease Management
C QGHSLAB Integrating Mental Health & Allergic Disease Management The Connection: Allergies significantly impact mental health, work productivity, and overall well- being. Patients with allergies are more likely to experience depression and anxiety. Key Insights: Hay fever sufferers have a 1.6x high
Slide 15: Q-Scale: Mental Health Insights for Better Care
Cy GHSLAB Q-Scale: Mental Health Insights for Better Care What It Does: The Q-Scale measures patients’ quality of life across sleep, stress, anxiety, pain, and overall life satisfaction. Identifies high-risk mental health concerns for early intervention. How It Works: 10-item questionnaire categoriz
Slide 16: The Demand for Mental Healthcare Grows
Cy QHSLAB The Demand for Mental Healthcare Grows Adults with medical illnesses are more likely to experience depression, and those with depression face a higher risk of chronic diseases. Chronic conditions affect 6 in 10 Americans, driving $4.1 trillion in annual healthcare costs. Mental health is a
Slide 17: Allergy: Key Products, Features and Proven Impact
@GHSIA Gp Allergy: Key Products, Features and Proven Impact Proven Impact: Serves a massive market: Over 150M Americans suffer from allergies, costing $16B annually in OTC and prescription treatments, by simplifying allergy care, QHSLab enables primary care providers to treat their patients, making
Slide 18: Addressing Allergies and Mental Health
CG QHSLAB Addressing Allergies and Mental Health ean anenay evweroms Have you had any of the following ear symptoms in the past few months? Enhanced Patient Care: Integrating allergy testing and treatment with mental health programs in primary care enables comprehensive patient care, improving outco
Slide 19: Market Opportunity and Growth Potential
Cy GHSLAB Market Opportunity and Growth Potential TAM (Total Addressable Market) + Mental Health Market: $1098 in 2023, projected to reach $167B by 2032. Allergy Testing Market: Rapid growth driven by increasing demand for in-office diagnostic solutions. SAM (Serviceable Available Market) + Primary
Slide 20: Competitive Landscape: QHSLab's Unique Position
CG QHSLAB Competitive Landscape: QHSLab's Unique Position in Mental Health and Allergy Solutions Mental Health Assessments: 1. Competitors: Online tools like Kaiser Permanente’s Mental Health Care Hub, and standalone platforms such as BetterHelp and Talkspace. 2. Challenges for Competitors: 1.Lack o
Slide 21: QHSLab's Unique Differentiators
Cy GHSLAB QHSLab’s: Unique Differentiators Comprehensive Suite: Combines mental health and allergy solutions in one platform, streamlining care for primary practices. Reimbursable Tools: Services align with CPT codes, ensuring seamless insurance reimbursement. Health Questionnaire Accessibility: Mak
Slide 22: Addressing Challenges: Building a Stronger Future
CG GHSLAB Addressing Challenges: Building a Stronger Future Acknowledging the Past Growth has been slower due to a deliberate focus on achieving product-market fit and navigating financial constraints, including managing convertible debt. Current Readiness QHSLab’s products are now clinically valida
Slide 23: Path Forward: Unlocking Growth with Strategic Investment
GW GHSLAB Path Forward: Unlocking Growth with Strategic Investment With a clear foundation in place, new investments will directly accelerate QHSLab's growth by addressing key priorities: Riase $1m in Equity: Free up cash flow to invest in scaling operations and expanding our reach. Expand Sales For
Slide 24: Empowering Physicians, Driving Revenue
CG QHSLAB Benefits to Doctors That D Annual Revenue (SM) 10 150 Number of Physicians 300 fe QHSLab's Revenue Empowering Physicians, Driving Revenue Nearly 50% of primary care physicians (~250,000) are independent, handling over 52% of all physician office visits. Innovative Solutions QHSLab's soluti
Slide 25: Positioned for Growth In a Changing Healthcare Landscape
CG QHSLAB Positioned for Growth In a Changing Healthcare Landscape + Allergy Care Gap: 60 million Americans suffer from allergic disorders, with fewer than 3,000 practicing allergists. Demand for allergy services is expected to rise by 35%, while the number of allergists is declining. Telemedicine A
Slide 26: Expanding Recurring Revenue
eae estore “Zathenahealth Expanding Recurring Revenue: Growing adoption of point-of-care and digital medicine services to boost revenue per client and exploring partnerships with MSOs, IPAs, and distributors to scale operations. Integration with electronic health records systems strengthens capabili
Slide 27: Expanding Our Presence and Thought Leadership
Cy QHSLAB Expanding Our Presence and Thought Leadership Parapet bs lationship ‘Mental and Physical Health ane Cx.) =_> tah Corporate Presentation - December 2025
Slide 28: Executive Leadership Team
QHSLAB Executive Leadership Team JEREMY JACOB, CHIEF TECHNOLOGY OFFICER With over two decades of experience, Jeremy has honed his technical expertise in crafting cutting-edge solutions centered around scalable cloud technology. He has an impressive track record of designing and launching innovative
Slide 29: General Inquiries
¥ QHSLAB General Inquiries hello@qhslab.com Investor Relations ir@usaqcorp.com QHSLab, Inc. 901 Northpoint Parkway Suite 302, West Palm Beach, FL 33407 www.ghslab.com Corporate Presentation - December 2025